Pestalozzi advises H.C. Wainwright in connection with CHF 20m private placement in Santhera Pharmaceuticals
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on the
development and commercialization of innovative medicines for rare neuromuscular and pulmonary
diseases with high unmet medical need listed at SIX Swiss Exchange, announced a CHF 20m private placement. H.C. Wainwright & Co. is acting as exclusive placement agent for the private placement, consisting of shares and purchase warrants. The aggregate gross proceeds from the private placement amount to approx. CHF 20m and potential gross proceeds from the purchase warrants amount to CHF 12.5m.
Pestalozzi advised H.C. Wainwright & Co. as to all matters of Swiss law and rules of the SIX Swiss Exchange.